Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Scientists Create New Antibody For Virus That Infects 95% of People : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-11

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredOne hope is that the antibodies could eventually be used to help prevent EBV-related post-transplant lymphoproliferative disorders in immunosuppressed transplant patients, especially children.View evidenceHide evidence

Why this verdict

The abstract-level profile supports only early translational relevance: EBV neutralizing antibodies showed protection in a humanized mouse challenge model and are framed as potential therapeutics. It does not verify the specific hoped-for use against post-transplant lymphoproliferative disorder, in immunosuppressed transplant patients, or especially in children. Because the story hedges this as a future hope rather than a proven clinical result, it is not overstated, but the specific clinical application is not verifiable from the abstract profile.

1

Study evidence

Passive delivery of a gp42-directed human monoclonal antibody protected humanized mice from EBV challenge.

“Delivery of a gp42 mAb protects humanized mice from EBV challenge”
Claim 2 of 5Not coveredThe article says the research has been published in Cell Reports Medicine and that the next stage is human safety testing and clinical trials.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include journal-publication metadata sufficient to verify publication in Cell Reports Medicine, and the abstract-level scientific profile does not state that the next stage is human safety testing and clinical trials. It does note that clinical safety, efficacy, and translatability are not addressed, so this claim cannot be verified at the supplied evidence depth.

Claim 3 of 5SupportedScientists at Fred Hutchinson Cancer Center and the University of Washington developed antibodies that target two proteins on the surface of Epstein-Barr virus particles.View evidenceHide evidence

As statedtwo proteins; 10 new antibodies

Why this verdict

The abstract-level profile supports that the researchers generated a panel of genetically human monoclonal antibodies against two EBV glycoproteins, gp350 and gp42, with counts of two anti-gp350 and eight anti-gp42 antibodies. The supplied profile does not independently verify the institutional affiliations, but the scientific substance and stated magnitude are supported.

1

Study evidence

Using a transgenic mouse model, the authors generated two gp350 and eight gp42 genetically human monoclonal antibodies.

“Using a transgenic mouse model, we generate two gp350 and eight gp42 genetically human neutralizing mAbs”
2

Study evidence

Generation of genetically human neutralizing monoclonal antibodies: two gp350-specific and eight gp42-specific mAbs were produced using a transgenic mouse platform.

“genetically human neutralizing mAbs that block receptor binding”
Claim 4 of 5SupportedIn experiments with mice carrying human-like immune systems, one of those antibodies protected the animals from EBV infection.View evidenceHide evidence

Why this verdict

The paper profile states that passive delivery of a gp42-directed monoclonal antibody protected humanized mice from EBV challenge. Because this was an in vivo experimental challenge model, the story's causal framing for protection in mice is supported at abstract depth, though quantitative details such as dose, animal numbers, endpoints, and statistics are not available.

1

Study evidence

Passive delivery of a gp42-directed human monoclonal antibody protected humanized mice from EBV challenge.

“Delivery of a gp42 mAb protects humanized mice from EBV challenge”
Claim 5 of 5SupportedThe researchers isolated 10 new antibodies in the lab — two targeting gp350 and eight targeting gp42 — and one showed particularly promising protection against EBV when tested in living mice.View evidenceHide evidence

As stated10 antibodies; 2 targeting gp350; 8 targeting gp42

Why this verdict

The profile supports the stated antibody panel: two gp350-targeting and eight gp42-targeting genetically human monoclonal antibodies. It also supports that a gp42 monoclonal antibody protected humanized mice from EBV challenge. The phrase 'particularly promising' is interpretive, but it is consistent with the abstract-level finding that the gp42 antibody protected mice while a gp350 antibody only partially protected them.

1

Study evidence

Using a transgenic mouse model, the authors generated two gp350 and eight gp42 genetically human monoclonal antibodies.

“Using a transgenic mouse model, we generate two gp350 and eight gp42 genetically human neutralizing mAbs”
2

Study evidence

Passive delivery of a gp42-directed human monoclonal antibody protected humanized mice from EBV challenge.

“Delivery of a gp42 mAb protects humanized mice from EBV challenge”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The antibodies were characterized as neutralizing and as blocking receptor binding: gp350 with complement receptors and gp42 with HLA class II.

    The story says the antibodies target EBV surface proteins and discusses mouse protection, but it does not reflect the abstract's in vitro receptor-blocking and neutralization findings or the specific receptor interactions.

    From in vitro binding/competition and cell-based neutralization assays

  • Structural analyses identified extended sites of vulnerability on gp350/gp42 relevant to vaccine development.

    The story presentation does not mention the paper's structural biology or epitope/vulnerability-site mapping component.

    From structural analyses / epitope mapping

  • A gp350 monoclonal antibody provided only partial protection in the humanized mouse model.

    The story presentation highlights one protective antibody but does not mention the comparator finding that a gp350 antibody had only partial protection, which is relevant to the balance of the in vivo results.

    From humanized mouse EBV challenge with passive mAb delivery

  • The abstract lacks key quantitative and methodological details for the animal protection experiment, including animal numbers, dosing, timing, endpoints, and statistical results.

    The story caveats mention that the work is early and that human testing remains ahead, but they do not acknowledge the abstract-level absence of quantitative animal-study details. This limits how strongly the mouse protection result can be interpreted.

    From humanized mouse EBV challenge with passive mAb delivery

3 things the story did carry across
  • The study generated a defined panel of genetically human EBV monoclonal antibodies: two targeting gp350 and eight targeting gp42.
  • In a humanized mouse EBV challenge model, passive delivery of a gp42 monoclonal antibody protected mice.
  • Human clinical efficacy, safety, dosing, manufacturability, and translatability are not addressed by the abstract-level paper evidence.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDemonstrate in vivo protection efficacy of selected gp42 and gp350 mAbs against EBV challenge in a humanized mouse model.humanized mouse EBV challenge with passive mAb deliveryExpand

In plain English

In a humanized mouse EBV challenge model, passive delivery of a transgenic-mouse-derived human gp42 monoclonal antibody protected mice from EBV challenge, whereas a gp350 monoclonal antibody produced partial protection.

Key findings

  • Passive delivery of a gp42-directed human monoclonal antibody protected humanized mice from EBV challenge.
  • Passive delivery of a gp350-directed human monoclonal antibody provided partial protection in the same humanized mouse EBV challenge model.
“Delivery of a gp42 mAb protects humanized mice from EBV challenge”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vivo animalGenerate genetically human neutralizing monoclonal antibodies (mAbs) against EBV gp350 and gp42 using a transgenic mouse platform and characterize their receptor-blocking/neutralizing activity.transgenic mouse antibody discoveryExpand

In plain English

Using a transgenic mouse platform, the authors generated a panel of genetically human neutralizing monoclonal antibodies against EBV glycoproteins gp350 (n=2) and gp42 (n=8); these mAbs block receptor binding, structural analyses identify extended vulnerability sites, and a gp42 mAb provided protection in humanized mice while a gp350 mAb gave partial protection.

Key findings

  • Using a transgenic mouse model, the authors generated two gp350 and eight gp42 genetically human monoclonal antibodies.
  • The generated mAbs are neutralizing and block receptor binding for EBV entry (gp350 interaction with complement receptors; gp42 interaction with HLA class II).
“Using a transgenic mouse model, we generate two gp350 and eight gp42 genetically human neutralizing mAbs”
What this piece can’t prove
  • Structural and in vivo protection descriptions lack methodological and quantitative detail (e.g., structural resolution, epitope mapping specifics, animal group sizes, dosing/regimen).

3 further details could not be confirmed from the summary.

3in vitroGenerate genetically human neutralizing monoclonal antibodies (mAbs) against EBV gp350 and gp42 using a transgenic mouse platform and characterize their receptor-blocking/neutralizing activity.in vitro binding/competition and cell-based neutralization assaysExpand

In plain English

Using a transgenic human antibody mouse platform the authors produced genetically human monoclonal antibodies (two targeting EBV gp350 and eight targeting gp42) and report in vitro functional characterization showing these mAbs block gp350–complement receptor interactions and gp42–HLA class II engagement and neutralize EBV entry in cell-based assays.

Key findings

  • Generation of genetically human neutralizing monoclonal antibodies: two gp350-specific and eight gp42-specific mAbs were produced using a transgenic mouse platform.
  • gp350-targeting mAbs block gp350 binding to complement receptors in in vitro receptor-blocking assays.
“genetically human neutralizing mAbs that block receptor binding”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vitroDefine structural epitopes/sites of vulnerability on gp350/gp42 targeted by the new mAbs to inform therapeutic/vaccine development.structural analyses / epitope mappingExpand

In plain English

Structural analyses of the newly generated human monoclonal antibodies against EBV gp350 and gp42 identified extended sites of vulnerability on one or both glycoproteins; the authors frame these sites as relevant to vaccine and therapeutic development.

Key findings

  • Structural analyses identify extended sites of vulnerability on EBV gp350 and/or gp42 that are targeted by the newly generated human neutralizing monoclonal antibodies; these sites are framed as relevant for vaccine development.
“Structural analyses reveal extended sites of vulnerability relevant to vaccine development.”
What this piece can’t prove
  • The claim of relevance to vaccine development is presented by the authors but the abstract does not provide supporting experimental or immunogenicity data for vaccine design.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Crystal structure of Epstein-Barr virus glycoprotein 350 (gp350) in complex with Cy651H02, a monoclonal antibody isolated from macaques immunized with a gp350 nanoparticle vaccine

Worldwide Protein Data Bank · 2024 · Crossref

Source (opens in a new tab)
Candidate

Structure of a human monoclonal neutralizing antibody S54 targeting Epstein-Barr virus major glycoprotein gp350

Worldwide Protein Data Bank · 2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.